TRIM21 and pulmonary fibrosis: We report and discuss the implications of the association between anti-Ro52 antibodies and lung fibrosis in a cohort of patients with idiopathic inflammatory myopathies, and we speculate that anti-Ro52 may represent a risk factor for PPF in these patients.